Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024 report and make more profitable business decisions.
Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function.
There are different types of peripheral neuropathy, each affecting specific nerves and causing varying symptoms: Sensory neuropathy, motor neuropathy, and autonomic neuropathy.
Sensory neuropathy primarily affects sensory nerves, leading to sensations of tingling, numbness, burning, increased sensitivity to touch, sharp or stabbing pains, and difficulty with coordination and balance. It can affect the hands, feet, arms, or legs.
Motor neuropathy affects motor nerves, resulting in muscle weakness, loss of coordination, or muscle cramps.
Autonomic neuropathy involves nerves regulating involuntary bodily functions, causing symptoms like changes in blood pressure, heart rate, digestion, sweating, and bladder control.
Peripheral neuropathy can have various causes. Diabetic neuropathy is one of the most common causes, affecting individuals with uncontrolled or poorly managed diabetes. Accidents, repetitive stress injuries, or trauma can damage nerves. Certain viral or bacterial infections like Lyme disease, HIV/AIDS, or shingles can lead to neuropathy. Exposure to toxins, such as heavy metals, certain medications, or chemicals, can damage nerves. Some forms of neuropathy are inherited.
The Peripheral Neuropathy (Sensory Neuropathy) drugs in development market research report provide comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Peripheral Neuropathy (Sensory Neuropathy) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 44 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Peripheral Neuropathy (Sensory Neuropathy) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Peripheral Neuropathy (Sensory Neuropathy) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Peripheral Neuropathy (Sensory Neuropathy) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akari Therapeutics PlcAlexion Pharmaceuticals Inc
Annexon Inc
Argenx SE
AstraZeneca Plc
Athira Pharma Inc
Augusta University
Boston Children's Hospital
Cellenkos Inc
Cellix Bio Pvt Ltd
Complement Pharma BV
Cresence AS
CSPC NBP Pharmaceutical Co Ltd
CuraVac Inc
CuroNZ Ltd
Dianthus Therapeutics Inc
EstryX Pharma Ltd
GeNeuro SA
Grifols SA
Hansa Biopharma AB
Helixmith Co Ltd
Immunovant Inc
Immupharma Plc
Johnson & Johnson
Kine Sciences
Malachite Innovations Inc
Nervosave Therapeutics
Neuropore Therapies Inc
New Biotic Inc
Octapharma AG
Peptron Inc
Polyneuron Pharmaceuticals AG
Regenacy Pharmaceuticals LLC
RegeneRx Biopharmaceuticals Inc
Releviate Therapeutics
Sanofi
Scenic Biotech BV
Serpin Pharma LLC
SwanBio Therapeutics Inc
Takeda Pharmaceutical Co Ltd
U.S. National Institutes of Health
Vertex Pharmaceuticals Inc
Washington University in St Louis
Zai Lab Ltd
Zenyaku Kogyo Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Peripheral Neuropathy (Sensory Neuropathy) reports